A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone
- PMID: 30449206
- DOI: 10.1080/17512433.2018.1549489
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone
Abstract
This is a combined analysis of therapeutic drug monitoring (TDM) studies of long-acting injectable paliperidone formulations: monthly (PP1M) and three-month (PP3M) injections. Areas covered: Fourteen PP1M articles and one PP3M article were identified. Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7.7 ng/ml per mg/day among 69 patients from three steady-state PP1M studies (twice as high as oral paliperidone). C/D ratios were: 1) higher by a factor of 1.26 in 12 geriatric patients, 2) lower in obese patients, and 3) 50% lower in three patients taking carbamazepine. No clinically meaningful PP3M pharmacokinetic data have been published. Expert commentary: Half-life studies and more TDM PP1M studies using steady state are urgently needed. Early TDM studies may help orient PP1M dosing but steady state may not be reached until after the ninth injection (8 months). PP3M may take > 1 year to reach steady state. Any clinician considering switching patients to PP1M: 1) should switch from oral risperidone to PP1M rather than from oral paliperidone to PP1M, and 2) become proficient in paliperidone TDM to use during switches. TDM is highly recommended for patients with abnormal clearance (from obesity, geriatric age, or potent inducers).
Keywords: Antipsychotic agents/administration & dosage; antipsychotic agents/pharmacology; delayed-action preparations; drug monitoring; injections; paliperidone palmitate; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; schizoaffective disorder/drug therapy; schizophrenia/drug therapy.
Similar articles
-
A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone.Expert Rev Clin Pharmacol. 2018 Jun;11(6):625-639. doi: 10.1080/17512433.2018.1478727. Epub 2018 Jun 18. Expert Rev Clin Pharmacol. 2018. PMID: 29776316
-
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.CNS Drugs. 2017 Apr;31(4):273-288. doi: 10.1007/s40263-017-0416-1. CNS Drugs. 2017. PMID: 28258365 Review.
-
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.Curr Med Res Opin. 2015 Nov;31(11):2043-54. doi: 10.1185/03007995.2015.1085849. Epub 2015 Oct 2. Curr Med Res Opin. 2015. PMID: 26306819
-
A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.Expert Rev Clin Pharmacol. 2017 Sep;10(9):965-981. doi: 10.1080/17512433.2017.1345623. Epub 2017 Jul 12. Expert Rev Clin Pharmacol. 2017. PMID: 28699847
-
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.Clin Drug Investig. 2018 Aug;38(8):695-702. doi: 10.1007/s40261-018-0647-z. Clin Drug Investig. 2018. PMID: 29882073 Clinical Trial.
Cited by
-
Clinical Correlates of Antipsychotic Plasma Levels with Long-Acting Paliperidone: Corrélats cliniques des concentrations plasmiques de palipéridone à libération prolongée.Can J Psychiatry. 2025 Mar;70(3):209-216. doi: 10.1177/07067437241295648. Epub 2024 Nov 15. Can J Psychiatry. 2025. PMID: 39544022 Free PMC article.
-
Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on East Asians.J Pers Med. 2022 Aug 24;12(9):1362. doi: 10.3390/jpm12091362. J Pers Med. 2022. PMID: 36143147 Free PMC article. Review.
-
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries.Epidemiol Psychiatr Sci. 2022 May 11;31:e34. doi: 10.1017/S2045796022000166. Epidemiol Psychiatr Sci. 2022. PMID: 35543395 Free PMC article.
-
Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database.Front Psychiatry. 2023 Apr 6;14:1130636. doi: 10.3389/fpsyt.2023.1130636. eCollection 2023. Front Psychiatry. 2023. PMID: 37091708 Free PMC article.
-
Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents.Pharmaceuticals (Basel). 2020 Dec 2;13(12):439. doi: 10.3390/ph13120439. Pharmaceuticals (Basel). 2020. PMID: 33276675 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources